Survival and glycemic control in patients with colorectal cancer and diabetes mellitus.

Karlin, Nina J.; Amin, Shailja; Verona, Patricia M; Kosiorek, Heidi E.; Buras, Matthew R.; Cook, Curtiss B.

doi:10.1200/jco.2018.36.15_suppl.e18755

Cited by 9 publications

(25 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…origins), with use of matched case-control methods to compare overall survival (OS) between patients with and without DM. These analyses showed that DM did not significantly impact OS in studies of individual cancer types and no significant effect on BG levels was detected [12][13][14][15][16].…”

mentioning

confidence: 92%

Assessing the Relationship Between Institutional Cancer and Diabetes Mortality Rates Using National Death Index Data

et al. 2020

View full text Add to dashboard Cite

Aim: To evaluate overall survival (OS), glycemic control in cancer patients with and without diabetes mellitus (DM). Patients & methods: Patients (2010–2015) with newly diagnosed prostate, breast, lung, colorectal and pancreatic cancers were identified in institutional cancer registry. Data linked to National Death Index for vital status. 5-year OS estimated; glucose and hemoglobin A1c assessed during year postdiagnosis. Results: We identified 1404 patients (non-DM, n = 936; DM, n = 468). DM cohort had 168 deaths (36%); non-DM, 267 (29%). 5-year OS estimated at 58% (95% CI: 53–64%) for DM and 67% (95% CI: 64–71%) for controls; for matched pairs, hazard ratio: 1.35 (95% CI: 1.02–1.79). Cancer did not harm glycemic control. Conclusion: OS among cancer patients with DM was lower than without DM.

show abstract

mentioning

confidence: 92%

Assessing the Relationship Between Institutional Cancer and Diabetes Mortality Rates Using National Death Index Data

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Several investigators, including our team, reported the co-occurrence of diabetes mellitus (DM) and colorectal cancer (CRC) along with bowel inflammation and dismicrobism [1–6]. Moreover, multiple reports suggested the involvement of the gut microbiome in the evolution of DM, and that potential modulation of the intestinal microbiota could prevent or delay its progression [7]. Furthermore, data are increasing about the greater risk for CRC in patients with DM by almost 1.2% to 1.5% [8].…”

Section: Introductionmentioning

confidence: 99%

A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin

et al. 2019

View full text Add to dashboard Cite

The link between colorectal cancer (CRC), diabetes mellitus (DM) and inflammation is well established, and polytherapy, including rapamycin, has been adopted. This study is a novel approach that aimed at assessing the effect of a combination therapy of metformin and rapamycin on the control or prevention of CRC in diabetic animals, in presence or absence of probiotics. Fifty NOD/SCIDs male mice developed xenograft by inoculating HCT116 cells. They were equally divided into diabetics (induced by Streptozotocin) and non-diabetics. Metformin was given in drinking water, whereas rapamycin was administered via intra-peritoneal injections. Probiotics were added to the double therapy two weeks before the sacrifice. Assessment was performed by clinical observation, histological analysis, Reactive oxygen species (ROS) activities and molecular analysis of Interleukin 3 and 6, Tumor Necrosis Factor alpha, AMP-activated protein Kinase and the mammalian target of rapamycin. Decreases in the level of tumorigenesis resulted, to various extents, with the different treatment regimens. The combination of rapamycin and metformin had no significant result, however, after adding probiotics to the combination, there was a marked delay in tumor formation and reduction of its size, suppression of ROS and a decrease in inflammatory cytokines as well as an inhibition of phosphorylated mTOR. Existing evidence clearly supports the use of rapamycin and metformin especially in the presence of probiotics. It also highlighted the possible mechanism of action of the 2 drugs through AMPK and mTOR signaling pathways and offered preliminary data on the significant role of probiotics in the combination. Further investigation to clarify the exact role of probiotics and decipher in more details the involved pathways is needed.

show abstract

“…It appears that diabetes mellitus does not decrease the survival of the CRC patients and CRC does not have a significant impact on glucose level of patients with diabetes mellitus [53,54]. In a study with high risk of CRC in comparison to controls but only among men [55].…”

Section: Discussionmentioning

confidence: 87%

Obesity, Diabetes and the Risk of Colorectal Adenoma and Cancer

Soltani

Poursheikhani

Yassi

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) is the fourth most commonly diagnosed gastrointestinal (GI) malignancy and the third leading cause of cancer-related death worldwide. In the current case-control study, an association between diagnosis of CRC, obesity and diabetes was investigated. Methods: Demographic characteristics, colonoscopy reports, history of drug, smoking, and medical history were collected from patients referred to a colonoscopy unit. The location, size and number of the polyps were recorded during the colonoscopy. Statistically, t -test was conducted for mean comparison for the groups. Pearson's chi-squared test (χ2) was applied to categorize variables. Five classification methods based on the important clinicopathological characteristics such as age, BMI, diabetes, family history of colon cancer was performed to predict the results of colonoscopy. Results: Overall, 693 patients participated in this study. In the present study, 115 and 515 patients were evaluated for adenoma/adenocarcinoma and normal colonoscopy, respectively. The mean age of patients positive for adenoma or adenocarcinoma were significantly higher than the negative groups (p value <0.001). Incidence of overweight and/or obesity (BMI> 25 kg/m2) were significantly higher in adenoma positive patients as compared to controls (49.9% and 0.9% respectively, p value= 0.04). The results also demonstrated a significant association between suffering from diabetes and having colon adenoma (OR=1.831, 95%CI=1.058–3.169, p value=0.023). The experimental results of 5 classification methods on higher risk factors between colon adenoma and normal colonoscopy data were more than 82% and less than 0.42 for the percentage of classification accuracy and root mean squared error, respectively. Conclusions: In the current study, the occurrence of obesity measured based on BMI and diabetes in the adenoma positive patient group was significantly higher than the control group although there was no notable association between obesity, diabetes and adenocarcinoma.

show abstract

Survival and glycemic control in patients with colorectal cancer and diabetes mellitus.

Cited by 9 publications

References 20 publications

Assessing the Relationship Between Institutional Cancer and Diabetes Mortality Rates Using National Death Index Data

Assessing the Relationship Between Institutional Cancer and Diabetes Mortality Rates Using National Death Index Data

A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin

Obesity, Diabetes and the Risk of Colorectal Adenoma and Cancer

Contact Info

Product

Resources

About